# get_semaglutide_adverse_events > Analyzes FDA FAERS adverse event reports for semaglutide (all formulations: Ozempic, Wegovy, Rybelsus). Provides comprehensive post-market safety surveillance including most reported adverse events by frequency, patient demographics, severity classifications, and specific tracking of key safety concerns (muscle mass loss, gallbladder issues, pancreatitis). - Author: uh-joan - Repository: uh-joan/agentic-os - Version: 20251211091835 - Stars: 0 - Forks: 0 - Last Updated: 2026-02-08 - Source: https://github.com/uh-joan/agentic-os - Web: https://mule.run/skillshub/@@uh-joan/agentic-os~get_semaglutide_adverse_events:20251211091835 --- --- name: get_semaglutide_adverse_events description: > Analyzes FDA FAERS adverse event reports for semaglutide (all formulations: Ozempic, Wegovy, Rybelsus). Provides comprehensive post-market safety surveillance including most reported adverse events by frequency, patient demographics, severity classifications, and specific tracking of key safety concerns (muscle mass loss, gallbladder issues, pancreatitis). category: regulatory mcp_servers: - fda_mcp patterns: - json_parsing - aggregation - demographic_analysis data_scope: total_results: 1000 geographical: US temporal: All time source: FDA FAERS database created: 2025-11-22 complexity: medium execution_time: ~4 seconds --- # get_semaglutide_adverse_events ## Sample Queries Examples of user queries that would invoke the pharma-search-specialist to create or use this skill: 1. `@agent-pharma-search-specialist What semaglutide adverse events drugs are FDA approved?` 2. `@agent-pharma-search-specialist Show me all approved semaglutide adverse events medications` 3. `@agent-pharma-search-specialist Get the list of FDA-approved drugs for semaglutide adverse events` Provides comprehensive adverse event analysis for semaglutide from FDA's Adverse Event Reporting System (FAERS), enabling post-market safety surveillance, risk management planning, and label update strategy. ## Key Safety Concerns Tracked - Muscle mass loss - Gallbladder issues - Pancreatitis - Gastrointestinal events (nausea, vomiting, diarrhea) - Patient demographics (age, gender) - Serious outcomes classification